Jesse Troy

Overview:

I am a biostatistician supporting research in cell therapies and regenerative medicine at the Duke Marcus Center for Cellular Cures, and research studies in cancer therapeutics and palliative care at the Duke Cancer Institute. I also teach biostatistics in the Master of Biostatistics program and the Clinical Research Training Program at Duke.

Positions:

Assistant Professor of Biostatistics & Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 2012

University of Pittsburgh

Grants:

Marcus Foundation Phase II MSC ASD

Administered By
Institutes and Centers
Awarded By
The Marcus Foundation
Role
Statistician
Start Date
End Date

"Understanding the Patient Experience of Stage 3 Unresectable Non-Small Cell Lung Cancer (NSCLC) in the Immuno-oncology Era"

Administered By
Duke Cancer Institute
Awarded By
AstraZeneca PLC
Role
Statistician
Start Date
End Date

Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers

Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

High Fidelity Diffusion MRI for Children with Cerebral Palsy in Stem Cell Therapy

Administered By
Duke-UNC Center for Brain Imaging and Analysis
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Publications:

Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization.

BACKGROUND: Limited English proficiency (LEP) is associated with adverse clinical outcomes. The clinical impact of LEP in hematopoietic stem cell transplant (HSCT) has not been studied. The objectives of this study were to compare HSCT outcomes and health care utilization of Hispanic pediatric patients with and without parental LEP. METHODS: We conducted a retrospective review of Hispanic/Latino pediatric patients receiving HSCT at a single institution. Families were identified as LEP or English proficient (EP) based on clinicians' notes, social work documentation, or the signature of a Spanish interpreter on treatment consents. RESULTS: A total of 83 Hispanic/Latino patients were identified with 53 (65.1%) having parental LEP. More patients in the LEP group had a documented financial burden at pretransplant psychosocial evaluation (72.2% vs. 41.4%, p = .009). LEP patients were more likely to have health insurance coverage through government-sponsored Medicaid (76.9% vs. 27.6%, p < .001). LEP patients were hospitalized on average 13 days longer than EP patients, and LEP patients were more likely to have pretransplant cytomegalovirus (CMV) reactivity (67.3%) than EP patients (p = .001). Overall survival was lower in LEP than EP, but was not statistically significant (p = .193). Multivariable Cox modeling suggested a potentially higher risk of death in LEP versus EP (hazard ratio = 1.56, 95% CI: 0.38, 6.23). CONCLUSIONS: Parental LEP in HSCT is associated with prolonged hospitalization and pretransplant CMV reactivity. These factors are associated with posttransplant complications and death. Our results suggest parental LEP is a risk factor for poor HSCT outcomes. Further study is warranted in a larger cohort.
MLA Citation
Robles, Joanna M., et al. “Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization.Pediatr Blood Cancer, vol. 68, no. 9, Sept. 2021, p. e29174. Pubmed, doi:10.1002/pbc.29174.
URI
https://scholars.duke.edu/individual/pub1484724
PMID
34109732
Source
pubmed
Published In
Pediatr Blood Cancer
Volume
68
Published Date
Start Page
e29174
DOI
10.1002/pbc.29174

Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

MDS are myeloid clonal hematologic disorders that are most commonly diagnosed in the seventh decade of life. Several treatment options are currently available. However, allo HSCT remains the only curative therapy. Unfortunately, despite the higher incidence of MDS in the older population, less than 10 % of patients undergoing allo HSCT for MDS are > 65 years old. In this paper we discuss the various treatment options in older patients with high-risk MDS with particular emphasis on the role of allo HSCT in older MDS patients.
Authors
Atallah, E; Bylow, K; Troy, J; Saber, W
MLA Citation
Atallah, Ehab, et al. “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).Curr Hematol Malig Rep, vol. 9, no. 1, Mar. 2014, pp. 57–65. Pubmed, doi:10.1007/s11899-013-0195-9.
URI
https://scholars.duke.edu/individual/pub1043340
PMID
24398726
Source
pubmed
Published In
Curr Hematol Malig Rep
Volume
9
Published Date
Start Page
57
End Page
65
DOI
10.1007/s11899-013-0195-9

The relationship between emotional well-being and understanding of prognosis in patients with acute myeloid leukemia (AML).

PURPOSE: Adults with acute myeloid leukemia (AML) face considerable distress and often have a poor prognosis. However, little is known about these patients' perceptions of prognosis and how this relates to emotional well-being (EWB). METHODS: We conducted a prospective, observational study of 50 adult patients with AML initiating chemotherapy, and surveyed them longitudinally for 6 months about their prognosis, treatment goals, quality of life, and EWB (by FACT-G). We derived a prognostic estimate for each patient based on data from published trials summarized in National Comprehensive Care Network Guidelines. We used descriptive statistics and longitudinal modeling to test the hypothesis that more accurate prognostic awareness is associated with worse EWB. RESULTS: Most patients (n = 43; 86%) had an objectively poor prognosis attributable to relapsed disease, complex karyotype, or FLT3 mutation. Yet, 74% of patients reported expecting a 50% or greater chance of cure. Patients with a poor prognosis more often had discordant prognostic estimates, compared to those with favorable risk AML (OR = 7.25, 95% CI 1.21, 43.37). Patient-reported prognostic estimates did not vary significantly over time. At baseline, patients who better understood their prognosis had worse EWB and overall quality-of-life scores (EWB 12 vs. 19.5; p = 0.01; FACT-G 65 vs. 75.5; p = 0.01). CONCLUSION: Patients with AML overestimate their prognosis, and awareness of a poor prognosis is associated with worse emotional well-being. Efforts are needed to improve patients' understanding of their prognosis, and to provide more psychosocial support and attention to well-being as part of high-quality leukemia care.
Authors
Singh, A; Locke, SC; Wolf, SP; Albrecht, TA; Troy, JD; Derry, H; El-Jawahri, A; LeBlanc, TW
MLA Citation
Singh, Anmol, et al. “The relationship between emotional well-being and understanding of prognosis in patients with acute myeloid leukemia (AML).Support Care Cancer, Aug. 2021. Pubmed, doi:10.1007/s00520-021-06499-w.
URI
https://scholars.duke.edu/individual/pub1493746
PMID
34401981
Source
pubmed
Published In
Support Care Cancer
Published Date
DOI
10.1007/s00520-021-06499-w

Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.

There is current interest in anti-angiogenesis therapies for head and neck squamous cell carcinomas (HNSCC), although the utility of these therapies in human papillomavirus (HPV) positive and HPV-negative HNSCC is unclear. Therefore, we explored heterogeneity in expression of a distal factor in angiogenesis (EGFR, the epidermal growth factor receptor), a proximal factor in angiogenesis (VEGF, the vascular endothelial growth factor) and a putative factor in angiogenesis (NOTCH1) in a HNSCC case series using immunohistochemistry in N = 67 cases (27 HPV-positive, 40 HPV-negative, by in situ hybridization). Box plots and the Wilcoxon rank sum or Kruskal-Wallis tests were used to compare staining scores (intensity × percent of cells staining) by HPV status and lifestyle factors. Associations between EGFR, VEGF, and NOTCH1 were assessed using box plots and Spearman correlation (ρ) in all cases, and stratified by HPV status. HPV-negative HNSCC over-expressed EGFR [median (range): 30 (0-300)] relative to HPV-positive HNSCC [7.5 (0-200)] (P = 0.006). VEGF and NOTCH1 were unrelated to HPV status (P > 0.05). EGFR was associated with VEGF in HPV-negative (ρ = 0.40, P = 0.01) but not HPV-positive HNSCC (ρ = 0.25, P = 0.20). NOTCH1 and VEGF were associated in HPV-negative (ρ = 0.40, P = 0.01) but not HPV-positive tumors (ρ = -0.12, P = 0.57). NOTCH1 was not associated with EGFR (P > 0.05). Our results are suggestive of heterogeneity in HNSCC angiogenesis. Future studies should explore angiogenesis mechanisms in HPV-positive and HPV-negative HNSCC.
Authors
Troy, JD; Weissfeld, JL; Youk, AO; Thomas, S; Wang, L; Grandis, JR
MLA Citation
Troy, Jesse D., et al. “Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Head Neck Pathol, vol. 7, no. 4, Dec. 2013, pp. 344–55. Pubmed, doi:10.1007/s12105-013-0447-y.
URI
https://scholars.duke.edu/individual/pub1043336
PMID
23645351
Source
pubmed
Published In
Head Neck Pathol
Volume
7
Published Date
Start Page
344
End Page
355
DOI
10.1007/s12105-013-0447-y

A machine learning approach for identifying predictors of success in a Medicaid-funded, community-based behavioral health program using the Child and Adolescent Needs and Strengths (CANS)

Authors
Troy, JD; Torrie, RM; Warner, DN
MLA Citation
Troy, Jesse D., et al. “A machine learning approach for identifying predictors of success in a Medicaid-funded, community-based behavioral health program using the Child and Adolescent Needs and Strengths (CANS).” Children and Youth Services Review, vol. 126, Elsevier BV, July 2021, pp. 106010–106010. Crossref, doi:10.1016/j.childyouth.2021.106010.
URI
https://scholars.duke.edu/individual/pub1489486
Source
crossref
Published In
Children and Youth Services Review
Volume
126
Published Date
Start Page
106010
End Page
106010
DOI
10.1016/j.childyouth.2021.106010

Research Areas:

Adolescent
Adult
Biostatistics
Cellular therapy
Child
Epidemiology
Head and Neck Neoplasms
Hematological oncology
Mouth Neoplasms
Myelodysplastic Syndromes
Pediatrics
Stem Cell Transplantation